Abstract:Transplant oncology is an expanding area of cancer therapy that specifically emphasizes the use of liver transplantation (LT) as the preferred treatment for patients with manageable, but unresectable, tumors. The management and optimization of overall survival strategies, accompanied by an arguably decent quality of life, have been at the forefront of liver oncology treatment, as a plurality of all primary liver cancers are identified as either hepatocellular carcinoma (HCC) or cholangiocarcinoma (CCA), which are classified as highly aggressive malignancies and frequently remain asymptomatic until they progress to advanced stages, rendering curative procedures, such as resection, impractical. This has led to an increase in utilization of neoadjuvant interventions conducted prior to surgery, which has yielded favorable outcomes. Though this treatment modality has prompted further investigations into the efficacy of immune checkpoint inhibitors (ICPIs) as standalone treatments and in combination with locoregional treatments (LRTs) to bridge more patients into curative eligibility. This multidisciplinary methodology and treatment planning has seen multiple successful trials of immunotherapy regimes and combinate treatments, setting the groundwork for increasing eligibility through downstaging and "bridging" previously ineligible patients within stringent LT criteria. Surveillance after LT is a crucial component of transplant oncology. The emergence of circulating tumor DNA (ctDNA) has provided a novel approach to identifying the recurrence of cancer in its early stages. Recent research has focused on liquid biopsy, a technique that effectively identifies the dynamics of cancer. This is another innovation to demonstrate the rate at which transplant oncology is rapidly advancing, making the focus of care feel disorienting. Modalities of care are constantly evolving, but when a field is changing as rapidly as this one, it is imperative to reorient to the data and the needs of the patients. In this commentary, we reflect on the update's utilization of ICPIs in neoadjuvant settings as well as the updates on the utilization of liquid biopsy in post-LT follow-up surveillance.

Liver Transplantation meets Cancer

Liver Transplant for Nonhepatocellular Carcinoma Malignancy

[Individualized curative treatment for malignant diseases through liver transplantation]

Liver transplantation meets gastrointestinal cancer

Liver transplantation for tumor entities

[New oncological indications for liver transplantation]

Liver Transplantation for Hepatocellular Carcinoma: A Narrative Review and A Glimpse into The Future

Recent Advances in Liver Transplantation for Hepatocellular Carcinoma

Expanding Indications for Liver Transplantation in the Treatment of Hepatocellular Carcinoma

A Glimpse Beyond the Liver

Liver Transplantation for Liver Cancer in the Era of Immunotherapy

Liver Transplantation for Intrahepatic Cholangiocarcinoma: Ready for Prime Time?

Focal Update on Immunotherapy and Liver Transplantation in the Era of Transplant Oncology

When Immunotherapy Meets Liver Transplantation for Hepatocellular Carcinoma:A Bumpy but Promising Road

Tumor-Associated Neutrophils: an Emerging Player in the Immune Microenvironment of Hepatocellular Carcinoma

New Scenarios in Liver Transplantation for Hepatocellular Carcinoma

Liver transplantation for primary and secondary liver tumors: Patient-level meta-analyses compared to UNOS conventional indications

Liver Transplant for Patients With Neuroendocrine Tumor: A Report of 2 Exceptional Cases and Literature Review.

Liver transplantation for hepatocellular carcinoma: Current status in Hong Kong, China

Evolution of transplant oncology indications: a single-institution experience over 40 years

Transplant Oncology: An Emerging Discipline of Cancer Treatment